Table 1.

PROTECT Trial, post-hoc analysis of ITTIV population

ITTIV population N = 299 (includes all patients from USA, Canada/Australia)	Low dose oral-heparin (60,000 IU/1.5 g SNAC) 30 days)	High dose oral-heparin (90,000 IU/2.25 g SNAC) 30 days	Injectable LOVENOX ® 30 mg s.c b.i.d.)10-day followed by placebo (to day 30)
Total DVT rate	27%	18%	28%
Relative Risk Reduction	4%	55%